Ten Years on the Juggernaut Keeps on Rolling: Comments on the STAMPEDE Trial from the Front Line

Affiliations

Editorial

A Birtle et al. Clin Oncol (R Coll Radiol). 2016 Sep.

. 2016 Sep;28(9):547-9.

doi: 10.1016/j.clon.2016.04.047. Epub 2016 May 25.

¹ Rosemere Cancer Centre, Preston, UK.
² Velindre Cancer Centre, Cardiff, UK. Electronic address: jim.barber@wales.nhs.uk.

No abstract available

Comment on

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.

Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.
Gilson C, Chowdhury S, Parmar MKB, Sydes MR; STAMPEDE Investigators. Gilson C, et al. Clin Oncol (R Coll Radiol). 2017 Dec;29(12):778-786. doi: 10.1016/j.clon.2017.10.004. Epub 2017 Oct 25. Clin Oncol (R Coll Radiol). 2017. PMID: 29079227 Free PMC article. Review.